endpoint of the study) favored ZD6474 (HR 0.69, P ϭ 0.025). The initial disease control rate (CR ϩ PR ϩ SD) also favored ZD6474 (53% versus 35%), as did the disease control rate after crossover (43% versus 24%). These data suggest that dual inhibition of EGFR and VEGF may be more effective than either strategy alone. In another randomized phase II trial, Heymach et al. 4 evaluated the benefits of combining ZD6474 with docetaxel versus docetaxel alone. Progression-free survival seemed superior with the combination.
If treatment with bevacizumab in the first-line setting is effective, is there any reason to think that treatment with it in the second-line setting would not be? Fehrenbacher et al. 5 tested this hypothesis in a randomized phase II study in which patients received chemotherapy (docetaxel or pemetrexed) plus placebo versus chemotherapy (docetaxel or pemetrexed) plus bevacizumab versus erlotinib plus bevacizumab. Prior use of bevacizumab was not permitted. Progression-free survival seemed to favor the bevacizumab-containing regimens, although no clear differences between the erlotinib-containing and chemotherapy-containing arms were appreciated.
Despite the encouraging results with each of these new agents, survival time for most patients in the second-line setting remains poor. However, subsets of patients seem to benefit more than others, underscoring the need to determine which targets are important in an individual patient. The path to improved outcomes must first come from recognizing that the empiric treatment of an unselected patient population will offer only a continuation of the minimal gains seen during the last 10 years. The appearance of a tumor under the microscope is but one superficial piece of information about the nature of the disease. It provides no information on the genetic makeup of the cancer, the dominant driver of growth, the mechanisms of resistance, the supporting environment, or the host that harbors it. Therefore, much in the same way we would not treat someone with breast cancer with trastuzumab who has a FISH-negative, but erb-2ϩ tumor defined by 1ϩ on immunohistochemistry, we should not treat someone with a targeted agent simply because we find the target. An excellent example of this in NSCLC is the recent discovery of the EGFR mutations and the likelihood of tumor response with the EGFR inhibitors in patients harboring these mutations, but lack of response in patients who only have overexpression of the receptor. 6 Furthermore, our interpretation of early trials must be carefully considered before proceeding to large phase III trials. Unfortunately, most phase III trials, which are based on "promising" phase II trials, are negative. Several clinical factors are widely known to predict better outcomes in second-or third-line phase II trials. In particular, detailed information on time since diagnosis of lung cancer, stage of original diagnosis, response to and duration of response to prior therapy, presence or absence of weight loss, number of sites of metastases, and specific sites of disease (liver, brain) must be considered. More emphasis should be given to agents active in refractory tumors, rather than only those active in patients with the most favorable disease characteristics, because it is the resistant disease that ultimately leads to the patients' deaths.
In conclusion, the war against lung cancer continues with new agents soon to be at our disposal. These advances are coming much too slowly, however, to affect the lives of millions of people who will confront advanced lung cancer during the next few years. We must continue to encourage willing, eligible patients to participate in clinical trials and to encourage all oncologists to participate in these trials. The advances of tomorrow will only be found with this approach. Finally, as we continue to test targeted agents in the secondand third-line setting, we must not lose sight of our primary target . . . tobacco, which is largely responsible for this worldwide calamity.
